



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** Anti-HIV-1 gp41 Monoclonal (F240)

**Catalog Number:** 7623

**Lot Number:** 160050

**Release Category:** C

**Provided:** 100 µg at 1.5 mg/ml, dialyzed into PBS and sterile filtered.  
Endotoxin = Less than 0.5 EU/ml

**Description:** A recombinant monoclonal antibody to gp41 (aa 592-606).

**Host:** CHO Cells

**Titer:** Immunoreactivity with gp41 was confirmed by ELISA and purity assessed by SDS-PAGE analysis.

**Special Characteristics:** This antibody is non-neutralizing and reacts with all subtypes of primary isolates of HIV-1. This antibody was produced in a CHO cell expression system and purified by protein G chromatography.

**Please Note: Previous Lots of Reagent 7623 were produced in a hybridoma cell system.**

[Click Here for ELISA and Purity Data.](#)

**Recommended Storage:** Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

**Contributor:** Dr. Marshall Posner and Dr. Lisa Cavacini.

**Isotype:** IgG<sub>1</sub>, K.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:** Cavacini LA, Emes CL, Wisniewski AV, Power J, Lewis G, Montefiori D, Posner MR. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. *AIDS Res Hum Retroviruses* **14**:1271-1280, 1998. [Abstract](#)

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp41 Monoclonal (F240) from Dr. Marshall Posner and Dr. Lisa Cavacini." Also include the reference cited above in any publications.

**Requests from commercial organizations should be directed to Michael Legregni, JD, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, BR2, Boston, MA 02215. Email: [mlegregn@bidmc.harvard.edu](mailto:mlegregn@bidmc.harvard.edu).**

**Last Updated** October 13, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.